Bryan Geoffrey Morton
Founder presso EUSA Pharma, Inc.
Profilo
Mr. Bryan G.
Morton is an Operating Partner at Essex Woodlands Health Ventures UK Ltd., an Executive Chairman at EUSA Pharma (UK) Ltd., an Executive Chairman at EUSA Pharma, Inc., a Chairman at Aircraft Medical Ltd., a Chairman at EUSA Pharma SAS, a Chief Financial Officer at Perspectum Diagnostics Ltd., an Independent Non-Executive Chairman at HealthCare Royalty Trust PLC and a Non-Executive Chairman at VHsquared Ltd.
He is on the Board of Directors at Syncona Partners LLP.
Mr. Morton was previously employed as a Non-Executive Chairman by Oxford BioTherapeutics Ltd., a President-International by Jazz Pharmaceuticals Plc, a Non-Executive Director by Dechra Pharmaceuticals PLC, a Non-Executive Chairman by Aircraft Medical Ltd., a Non-Executive Chairman by ReNeuron Group Plc, a Chief Executive Officer by Zeneus Pharma Ltd., a Senior Vice President & Director-Europe Region by Bristol-Myers Squibb Co., a President-EMEA by ConvaTec, Inc., a Chairman by Glide Pharmaceutical Technologies Ltd., and a General Manager & Head-Europe Division by Merck & Co., Inc. He also served on the board at Oxtex Ltd.
He received his undergraduate degree from the University of Aberdeen and an MBA from the University of Durham.
Posizioni attive di Bryan Geoffrey Morton
| Società | Posizione | Inizio |
|---|---|---|
EUSA Pharma, Inc.
 EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Founder | 01/01/2005 |
EUSA Pharma SAS
 EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Chairman | 09/02/2010 |
EUSA Pharma (UK) Ltd.
 EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | Chairman | 01/01/2006 |
| Essex Woodlands Health Ventures UK Ltd. | Private Equity Investor | 01/01/2017 |
Essex Woodlands Management, Inc.
 Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Private Equity Investor | - |
Precedenti posizioni note di Bryan Geoffrey Morton
| Società | Posizione | Fine |
|---|---|---|
Syncona Partners LLP
 Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Director/Board Member | 02/01/2020 |
Perspectum Ltd.
 Perspectum Ltd. Medical/Nursing ServicesHealth Services Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom. | Director of Finance/CFO | 24/12/2016 |
| RENEURON GROUP PLC | Chairman | 01/04/2015 |
| DECHRA PHARMACEUTICALS | Director/Board Member | 09/07/2012 |
| ░░░░░░ ░░░░░░ ░░░░ | ░░░░░░░ | ░░░░░░░░░░ |
Formazione di Bryan Geoffrey Morton
| University of Aberdeen | Undergraduate Degree |
| University of Durham | Masters Business Admin |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 5 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| MERCK & CO., INC. | Health Technology |
| RENEURON GROUP PLC | Health Technology |
| DECHRA PHARMACEUTICALS | Health Technology |
| JAZZ PHARMACEUTICALS PLC | Health Technology |
| Aziende private | 15 |
|---|---|
Zeneus Pharma Ltd.
 Zeneus Pharma Ltd. Medical DistributorsDistribution Services Zeneus Pharma Ltd. provides pharmaceutical products. It offers license to late-stage development, pre and post-approval, and marketing services across Europe for specialty hospital medicines. The company was founded in 2004 by Bryan Morton and is headquartered in Oxford, UK. | Distribution Services |
EUSA Pharma, Inc.
EUSA Pharma, Inc. Pharmaceuticals: MajorHealth Technology EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight products on the market, including Caphosol for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high-dose chemotherapy, ProstaScint for imaging the extent and spread of prostate cancer, Quadramet for the treatment of pain in patients whose cancer has spread to the bones, Erwinase and Kidrolase for the treatment of acute lymphoblastic leukemia and the antibiotic surgical implant Collatamp. EUSA also has several products in late-stage development, notably Collatamp topical, a gentamicin impregnated collagen sponge for the prevention and treatment of infected skin ulcers, and CollaRx bupivacaine implant for local post-surgical pain control. Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising TVM Capital, Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, NeoMed and NovaQuest. Since its foundation, the company has raised over $275 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Ltd, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. As part of its rapid growth strategy the company has established commercial infrastructure in the US, a pan-European presence covering over 20 countries and a wider distribution network in a further 25 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing within its specialist areas of medical and geographic focus, in line with its ambitious target to create a rapidly growing $1 billion company by the beginning of the next decade. | Health Technology |
Oxford BioTherapeutics Ltd.
 Oxford BioTherapeutics Ltd. Pharmaceuticals: MajorHealth Technology Oxford BioTherapeutics Ltd. develops antibody-based medicines for oncology. The firm offers antibody-based cancer drugs with integrated diagnostics against novel targets. The company was founded by Christian Rohlff in 2003 and is headquartered in Abingdon, the United Kingdom. | Health Technology |
Aircraft Medical Ltd.
 Aircraft Medical Ltd. Medical SpecialtiesHealth Technology Aircraft Medical Ltd. develops and produces medical devices that focus on the needs of anesthesia and critical care professionals. It offers video scope, video laryngoscope, medical device, laryngoscope, difficult intubation, camera stick, airway management and difficult airway management. The company was founded by Matthew John Ross McGrath in June 2001 and is headquartered in Edinburgh, the United Kingdom. | Health Technology |
ConvaTec, Inc.
 ConvaTec, Inc. Medical SpecialtiesHealth Technology ConvaTec, Inc. engages in the manufacture of medical products and technologies focused on therapies for the management of chronic conditions. It specializes in the wound care, ostomy care, continence and critical care, and infusion devices. The company was founded in 1978 and is headquartered in Bridgewater, NJ. | Health Technology |
Essex Woodlands Management, Inc.
Essex Woodlands Management, Inc. Investment ManagersFinance Essex Woodlands Management, Inc. (EW Healthcare Partners) is a private equity firm founded in 1985 by Jim L. Currie and Martin P. Sutter. The firm is headquartered in Houston, Texas. | Finance |
| Essex Woodlands Health Ventures UK Ltd. | Finance |
Glide Pharmaceutical Technologies Ltd.
 Glide Pharmaceutical Technologies Ltd. Pharmaceuticals: MajorHealth Technology Glide Pharmaceutical Technologies Ltd. developed and manufactured pharmaceutical products. The firm developed SDI, a solid dose injector system to improve compliance in patients self-administering long term therapy. Its pipeline of solid dose formulations includes octreotide, teriparatide, and anthrax and influenza vaccines. It also engaged in developing a non-invasive diagnostic technology that primarily focuses on prostate cancer, which aims to identify clinically significant disease based on a biochemical marker. The company was founded by Charles David Ogilvy Potter on 6th March, 2001 and was headquartered in Abingdon, the United Kingdom. | Health Technology |
EUSA Pharma SAS
EUSA Pharma SAS BiotechnologyHealth Technology EUSA Pharma SAS specializes in pharmaceutical research for rare diseases. The company was founded by Gilles Alberici on September 24, 1999 and is headquartered in Limonest, France. | Health Technology |
Oxtex Ltd.
 Oxtex Ltd. Medical SpecialtiesHealth Technology Oxtex Ltd. operates as an early-stage medical device company. It develops novel devices for soft tissue expansion. The firm's technology comprises implantable self-inflating tissue expanders available in sizes and shapes to suit the specific needs of the clinician and the patient. The company was founded by Jan Tadeusz Czernuszka and David Edward Jackson in May 2011 and is headquartered in Witney, the United Kingdom. | Health Technology |
Perspectum Ltd.
Perspectum Ltd. Medical/Nursing ServicesHealth Services Perspectum Ltd. provides technology solutions for diagnosing and staging liver disease. The company was founded by Rajarshi Banerjee, Stefan Karl Neubauer, Matthew David Robson, Alastair Cavanagh, James Hugh Charteris Mallinson and John Michael Brady on September 18, 2012 and is headquartered in Oxford, the United Kindgom. | Health Services |
VHsquared Ltd.
 VHsquared Ltd. BiotechnologyHealth Technology VHsquared Ltd. develops antibody domain products. It operates as a development stage biologics company which develops a portfolio of orally delivered antibody domain products for gastro intestinal health. The company's novel antibody platform will provide a portfolio of new and innovative functional food products to target gastrointestinal infectious and immune mediated diseases. VHsquared leverages the existing research and expertise at the Sanger Institute to facilitate the development of products that function at the gastro intestinal mucosal interface harnessing recent technological developments, including analysis of the micro biota and advances in mucosal immunology. VHsquared was founded in 2010 by William Roderick Justin Richards, Janet Rosemary Robinson, James Scott Crowe, and Gordon Dougan and is headquartered in Cambridge, the United Kingdom. | Health Technology |
Syncona Partners LLP
Syncona Partners LLP Investment ManagersFinance Syncona Partners LLP (Syncona Partners) is a venture capital subsidiary of Syncona Investment Management Ltd. founded in 2012 by Martin Murphy. The firm is headquartered in London, United Kingdom. | Finance |
EUSA Pharma (UK) Ltd.
EUSA Pharma (UK) Ltd. Medical DistributorsDistribution Services EUSA Pharma (UK) Ltd. supplies medicines and medical devices. It offers Caphosol, Xenazine, Collatamp, Custodiol, and Fomepizole. The company was founded in March 2015 and is headquartered in Hemel Hempstead, the United Kingdom. | Distribution Services |
HealthCare Royalty Trust PLC
 HealthCare Royalty Trust PLC Investment Trusts/Mutual FundsMiscellaneous HealthCare Royalty Trust PLC is a closed-ended investment fund which intended to establish one or more wholly-owned subsidiaries for efficient portfolio management. The company was founded on December 15, 2015 and is headquartered in London, the United Kingdom. | Miscellaneous |
- Borsa valori
- Insiders
- Bryan Geoffrey Morton
